StockNews.AI
MBX
StockNews.AI
3 hrs

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

1. MBX to participate in Stifel 2025 Cardiometabolic Forum on Sept 30. 2. Key executives will discuss novel precision peptide therapies. 3. Pipeline includes Phase 2 developments for chronic disorders. 4. Company focuses on unmet medical needs in endocrine treatments.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive visibility at the forum may attract investor interest, reminiscent of successful presentations by other biotech firms that spurred stock gains.

How important is it?

Engagement in forums highlights growth potential and enhances market visibility, crucial for a clinical-stage company.

Why Short Term?

Immediate investor interest expected following the forum, similar to past impacts from key industry events.

Related Companies

PFEAMGNBMY
September 29, 2025 08:00 ET  | Source: MBX Biosciences, Inc. CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, MD, Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum on September 30. Stifel 2025 Virtual Cardiometabolic ForumDate: Tuesday, September 30, 2025Format: Fireside chatTime: 10:00 a.m. – 10:25 a.m. ETLocation: Virtual The live webcast of the presentation can be accessed in the events sections of MBX’s website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website for approximately 90 days. About MBX Biosciences MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; imapextide (1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn. Media Contact:Katie Beach OltsikInizio Evoke Commskatie.beach@inizioevoke.com    (937) 232-4889 Investor Contact:Jim DeNikeMBX Biosciencesjdenike@mbxbio.com

Related News